biostudies-literatureWu RBritish Heart FoundationBarts CharityMedical Research CouncilNational Institute for Health Research (NIHR)e189-e198https://www.ebi.ac.uk/biostudies/studies/S-EPMC10904120biostudies-literatureUnknown74(740)<h4>Background</h4>UK cardiovascular disease (CVD) incidence and mortality have declined in recent decades but socioeconomic inequalities persist.<h4>Aim</h4>To present a new CVD model, and project health outcomes and the impact of guideline-recommended statin treatment across quintiles of socioeconomic deprivation in the UK.<h4>Design and setting</h4>A lifetime microsimulation model was developed using 117 896 participants in 16 statin trials, 501 854 UK Biobank (UKB) participants, and quality-of-life data from national health surveys.<h4>Method</h4>A CVD microsimulation model was developed using risk equations for myocardial infarction, stroke, coronary revascularisation, cancer, and vascular and non-vascular death, estimated using trial data. The authors calibrated and further developedThe British journal of general practice : the journal of the Royal College of General PractitionersLong-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.PMC1090412017/140/02MGU0421MR/R024227/1CH/1996001/9454NIHR203330Robson JNeil AGlynn RLandray MZannad FHaynes RLonn ESerruys PWWilson KClearfield MMihaylova BWedel HWilliams CWanner CNicolis EBBlauw GJVarigos JMacFadyen JArashi HSacks FPedersen TRHoldaas HBlackwell LReith CSmeeth LTonkin ADowns JRKean SHawkins CMYamamguchi JKnopp RHCobbe STognoni GYoung RDavies KWelch KMBraunwald ETavazzi LMoye LWhite HBetteridge DJBlazing MLucci DSever PSattar NKnatterud GShepherd JKoren MMarchioli RBaigent CShaw JZhou JKrane VRidker PMHolland LProbstfield JLMaggioni AKastelein JJSleight PParish SHovingh GKGoldbourt UGray AKirby AKeech ACannon CPSimpson LFulcher JFord IPressel SDurrington PNBowman LArmitage JYusuf SClarke RHalls HFellstrom BGoto SSimes JGupta AHerrington WGGotto AWikstrand JJardine AWu RBarter PDavis BColhoun HMO'Connell RWiviott SHopewell JRahman MSchwartz GGDahlof BAmarenco PSabatine MSSchlackow IMacMahon STobert JBosch JBarnes EKitas GPoulter NRoberston MFlather MFranzosi MGPeto RMacfarlane PGrimm RNewman CMarschner IFurberg CKjekshus JEmberson JMurphy SSchmieder RWilhelmsen LPfeffer MCTT Collaboration secretariat CTT Collaboration trialists: A to Z trial (phase Z) AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study)ALERT (Assessment of Lescol in Renal Transplantation)ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events)ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabetes Mellitus)AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events)CARDS (Collaborative Atorvastatin Diabetes Study)CARE (Cholesterol And Recurrent Events Study)CORONA (Controlled RosuvasHitman GALemos JKoenig WCollins RBulbulia RPreiss DLatini RGordon DWeis SPackard CFuller JTrompet SLaRosa JfalseLong-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.<h4>Background</h4>UK cardiovascular disease (CVD) incidence and mortality have declined in recent decades but socioeconomic inequalities persist.<h4>Aim</h4>To present a new CVD model, and project health outcomes and the impact of guideline-recommended statin treatment across quintiles of socioeconomic deprivation in the UK.<h4>Design and setting</h4>A lifetime microsimulation model was developed using 117 896 participants in 16 statin trials, 501 854 UK Biobank (UKB) participants, and quality-of-life data from national health surveys.<h4>Method</h4>A CVD microsimulation model was developed using risk equations for myocardial infarction, stroke, coronary revascularisation, cancer, and vascular and non-vascular death, estimated using trial data. The authors calibrated and further developed2024-01-01T00:00:00Z2024 Mar2026-07-15T00:47:00.084Z2026-06-27T03:04:49.122ZS-EPMC109041203837385110.3399/BJGP.2023.0198